PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9211083-1	1997	Troglitazone decreases insulin resistance (improves insulin sensitivity), which results in reduced plasma glucose and insulin levels in patients with non-insulin-dependent diabetes mellitus (NIDDM).	Troglitazone	0-12	insulin	Homo sapiens	23-30	
9211083-1	1997	Troglitazone decreases insulin resistance (improves insulin sensitivity), which results in reduced plasma glucose and insulin levels in patients with non-insulin-dependent diabetes mellitus (NIDDM).	Troglitazone	0-12	insulin	Homo sapiens	52-59	
9211083-2	1997	Risk factors for cardiovascular disease such as elevated proinsulin and triglyceride levels are also reduced by troglitazone.	Troglitazone	112-124	insulin	Homo sapiens	57-67	
9211083-3	1997	In clinical trials, troglitazone 200 to 800 mg daily (alone or in combination with other oral antidiabetic agents or insulin) reduced plasma or serum glucose levels and glycosylated haemoglobin compared with both baseline and placebo in patients with NIDDM refractory to other oral antidiabetic agents (usually sulphonylureas).	Troglitazone	20-32	insulin	Homo sapiens	117-124